MWNA
CHRS icon

Marshall Wace North America’s Coherus Oncology CHRS Stock Holding History

Marshall Wace North America’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-24,133
Closed -$352K – 1493
2021
Q1 		$352K Buy
+24,133
New +$410K ﹤0.01% 1277
2018
Q4 		– Sell
-21,466
Closed -$354K – 1490
2018
Q3 		$354K Sell
21,466
-618,793
-97% -$11M ﹤0.01% 761
2018
Q2 		$8.96M Buy
640,259
+625,100
+4,124% +$8.95M 0.05% 355
2018
Q1 		$168K Buy
15,159
+3,647
+32% +$39.9K ﹤0.01% 1348
2017
Q4 		$101K Buy
+11,512
New +$123K ﹤0.01% 1315
2017
Q2 		– Sell
-63,374
Closed -$1.33M – 1306
2017
Q1 		$1.33M Buy
+63,374
New +$1.56M 0.01% 652

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Marshall Wace North America's CHRS Position: Q2 2021 in Review

Marshall Wace North America sold out of Coherus Oncology (CHRS) in Q2 2021, closing a stake of 24,133 shares — an estimated $352K sold.

Marshall Wace North America first reported a position in CHRS in Q1 2017 and held it in 6 quarters. The position peaked at $8.96M in Q2 2018. 188 funds tracked by Wall St. Rank hold CHRS as of Q2 2021.

  • Marshall Wace North America reported no remaining Coherus Oncology position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 24,133 Coherus Oncology shares in Q2 2021, an estimated $352K.
  • Marshall Wace North America first reported a position in Coherus Oncology in Q1 2017 and held it in 6 quarters.
  • Marshall Wace North America's Coherus Oncology position peaked at $8.96M in Q2 2018.
  • 188 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.